Available IPD datapackage for study 'A Multicenter, Prospective, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effect of Fluvoxamine, Ivermectin, Doxasozin and Interferon Lambda 1A in Mild COVID-19 and High Risk of Complications'

The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in
certain subgroups of patients. To date, no treatment has been shown to be effective in
patients with early-onset disease and mild symptoms. Experimental studies have demonstrated a
potential anti-inflammatory role of Fluvoxamine, Metformin and Ivermectin in SARS-CoV-2
infections and observational studies have suggested a reduced complications in patients with
COVID-19 disease.